Bibliography
- Lauer MS . Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk. JAMA297, 1376–1378 (2007).
- Ware JE Jr , SherbourneCD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care. 30, 473–483 (1992).
- Wang TJ , GonaP, LarsonMGet al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 355, 2631–2639 (2006).
- Melander O , Newton-ChehC, AlmgrenPet al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA302, 49–57 (2009).
- Kim HC , GreenlandP, RossouwJEet al. Multimarker prediction of coronary heart disease risk: the Women’s Health Initiative. J. Am. Coll. Cardiol. 55, 2080–2091 (2010).
- Schnabel R , LubosE, RupprechtHJet al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J. Am. Coll. Cardiol. 47, 552–558 (2006).
- Olsen MH , HansenTW, ChristensenMKet al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur. Heart J. 28, 1374–1381 (2007).
- Zethelius B , BerglundL, SundstromJet al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N. Engl. J. Med. 358, 2107–2116 (2008).
- Daniels LB , LaughlinGA, CloptonP, MaiselAS, Barrett-ConnorE. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J. Am. Coll. Cardiol. 52, 450–459 (2008).
- Blankenberg S , ZellerT, SaarelaOet al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation121, 2388–2397 (2010).
- Oemrawsingh RM , LenderinkT, AkkerhuisKMet al. Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome. Heart97, 1061–1066 (2011).
- Sabatine MS , MorrowDA, de Lemos JAet al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 105, 1760–1763 (2002).
- Velagaleti RS , GonaP, LarsonMGet al. Multimarker approach for the prediction of heart failure incidence in the community. Circulation122, 1700–1706 (2010).
- Nozaki T , SugiyamaS, KogaHet al. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J. Am. Coll. Cardiol. 54, 601–608 (2009).
- Pascual-Figal DA , Manzano-HernandezS, BoronatMet al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur. J. Heart Fail. DOI: 10.1093/eurjhf/hfr047 (2011) (Epub ahead of print).
- Paynter NP , ChasmanDI, PareGet al. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA303, 631–637 (2010).